LGVN Q2 2023 Earnings — Longeveron Inc. Revenue & Financial Results | Market Cap Arena

LGVNLongeveron Inc.

$20M

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$217,000-53.4% YoY

Gross Profit

$93,00042.9% margin

Operating Income

-$6M-2632.3% margin

Net Income

-$6M-2595.4% margin

EPS (Diluted)

$-2.67

QoQ Revenue Growth

-8.8%

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$5M

Stock-Based Comp.

$700,000

Balance Sheet

Total Assets

$17M

Total Liabilities

$6M

Stockholders' Equity

$11M

Cash & Equivalents

$3M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$217,000	$466,000	-53.4%
Gross Profit	$93,000	$160,000	-41.9%
Operating Income	-$6M	-$4M	-35.3%
Net Income	-$6M	-$6M	-0.1%